Observational studyTheranostics2020
P2RX7B is a new theranostic marker for lung adenocarcinoma patients.
Observational study in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 37 citations in OpenAlex.
- Methodological guidelines for P2X receptor assays and data interpretation.Cell death & disease · 2026Review
- P2X7 receptor: a potential therapeutic target for chronic respiratory diseases.Molecular and cellular biochemistry · 2026Review
- Functional role of P2X7 purinergic receptor in cancer and cancer-related pain.Purinergic signalling · 2025Review
- Article
- Comprehensive insights into potential roles of purinergic P2 receptors on diseases: Signaling pathways involved and potential therapeutics.Journal of advanced research · 2025Review
- Role and Therapeutic Potential of P2X7 Receptor in Lung Cancer Progression.Current medicinal chemistry · 2025Review
- P2X7 Variants in Pathophysiology.International journal of molecular sciences · 2024Review
- The P2X7 Receptor in Oncogenesis and Metastatic Dissemination: New Insights on Vesicular Release and Adenosinergic Crosstalk.International journal of molecular sciences · 2023Review
- The Role of IL-18 in P2RX7-Mediated Antitumor Immunity.International journal of molecular sciences · 2023Review
- Medical insurance payment schemes and patient medical expenses: a cross-sectional study of lung cancer patients in urban China.BMC health services research · 2023Article
- Protocol for Evaluating In Vivo the Activation of the P2RX7 Immunomodulator.Biological procedures online · 2023Article
- Purinergic signaling: Diverse effects and therapeutic potential in cancer.Frontiers in oncology · 2023Review
- Tumour immune escape via P2X7 receptor signalling.Frontiers in immunology · 2023Review
- Alternatively Spliced Isoforms of the P2X7 Receptor: Structure, Function and Disease Associations.International journal of molecular sciences · 2022Review
- The Purinergic Landscape of Non-Small Cell Lung Cancer.Cancers · 2022Review
- Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor modelsFrontiers in immunology · 2022Article
- To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question.Purinergic signalling · 2021Review
- The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties.Journal of bone oncology · 2021Article
- P2X7 promotes metastatic spreading and triggers release of miRNA-containing exosomes and microvesicles from melanoma cells.Cell death & disease · 2021Article
- Autocrine and paracrine purinergic signaling in the most lethal types of cancer.Purinergic signalling · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.